1. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
   Rajiv Kumar et al, 2016, Cancer Chemotherapy and Pharmacology CrossRef
2. Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature
   Zhengwu Tang et al, 2020, Lung Cancer CrossRef
3. Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?
   Xavier Mignard et al, 2019, Bulletin du Cancer CrossRef
4. Rechallenge Strategy in Cancer Therapy
   Ekaterina Hanovich et al, 2020, Oncology CrossRef
5. Successful Pemetrexed Rechallenge Chemotherapy in Advanced Pulmonary Adenocarcinoma
   Toshi Murakami et al, 2016, Haigan CrossRef
6. Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)
   Florian Rosar et al, 2024, European Journal of Nuclear Medicine and Molecular Imaging CrossRef
7. Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
   Stefania Crucitta et al, 2022, Cancer Treatment Reviews CrossRef